Fig. 4

Roles of ACE2 in predicting clinical and immune phenotypes in the recruited TMA cohort. A Schematic protocol of validation on the TMA cohort. B Representative images revealing ACE2 expression in tumor and para-tumor tissues using anti-ACE2 staining. Magnification, 200 × . C Expression levels of ACE2 in tumor and para-tumor tissues. Significance was calculated with Mann Whitney test for ER and PR status and Student’s t-test for HER2 and TNBC status. *P < 0.05. D Representative images revealing ACE2 expression in BC tissues with different molecular features. Magnification, 200 × . E Expression levels of ACE2 in various molecular subtypes. Significance was calculated with Student’s t-test. *P < 0.05. F Representative images revealing CD8⁺ T cell infiltration and PD-L1 expression in the high and low ACE2 groups. Magnification, 200 × . G Differences in CD8⁺ T cell infiltration between the high and low ACE2 groups. Significance was calculated with Student’s t-test. *P < 0.05. H Differences in PD-L1 expression between the high and low ACE2 groups. Significance was calculated with Student’s t-test. *P < 0.05. I Representative images uncovering CD8.⁺ T cell infiltration and ACE2 expressions in BC tissues with different immuno-phenotypes. Magnification, 200 × . J Expression of ACE2 in BC with different immuno-phenotypes. Significance was calculated with One-way ANOVA with Tukey’s multiple comparisons test. ns-P > 0.05, **P < 0.01, ***P < 0.001